These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34172507)

  • 21. New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo.
    Ocaña MC; Bernal M; Yang C; Caro C; Domínguez A; Vu HS; Cárdenas C; García-Martín ML; DeBerardinis RJ; Quesada AR; Martínez-Poveda B; Medina MÁ
    Commun Biol; 2023 Oct; 6(1):1084. PubMed ID: 37880317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.
    Comi G; Leocani L; Ferini-Strambi L; Radaelli M; Costa GD; Lanzillo R; Lus G; Bianchi V; Traccis S; Capone F; Grimaldi LM; Salemi G; Cardillo A; Zipoli V;
    Mult Scler J Exp Transl Clin; 2023; 9(1):20552173221144229. PubMed ID: 36776745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diroximel fumarate to treat multiple sclerosis.
    Wang Y; Bhargava P
    Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.
    Mori M; Ohashi T; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Mult Scler J Exp Transl Clin; 2019; 5(2):2055217319852727. PubMed ID: 31218077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate.
    Popiel M; Psujek M; Bartosik-Psujek H
    Mult Scler Relat Disord; 2018 Nov; 26():204-206. PubMed ID: 30268042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.
    Hersh CM; Love TE; Bandyopadhyay A; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler J Exp Transl Clin; 2017; 3(3):2055217317715485. PubMed ID: 28890796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do dimethyl fumarate and nicotinic acid elicit common, potentially HCA
    Dubrall D; Pflock R; Kosinska J; Schmid M; Bleich M; Himmerkus N; Offermanns S; Schwaninger M; Sachs B
    Br J Clin Pharmacol; 2021 Oct; 87(10):3813-3824. PubMed ID: 33605454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.
    Sałacińska D; Pogoda A; Żółkiewicz J; Stępień A
    Pol Merkur Lekarski; 2019 Dec; 47(282):221-225. PubMed ID: 31945023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study.
    Højsgaard Chow H; Talbot J; Lundell H; Marstrand L; Gøbel Madsen C; Bach Søndergaard H; Bredahl Hansen M; Solberg Sørensen P; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2023 Feb; 70():104458. PubMed ID: 36586351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria.
    Sator P; Loewe R; Zamani O; Holzer G; Wolf P; Mlynek A; Berger T; Richter L; Schuller E
    Wien Klin Wochenschr; 2019 Oct; 131(19-20):485-492. PubMed ID: 31591676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA methylation changes in CD4
    Maltby VE; Lea RA; Ribbons KA; Sanders KA; Kennedy D; Min M; Scott RJ; Lechner-Scott J
    Mult Scler J Exp Transl Clin; 2018; 4(3):2055217318787826. PubMed ID: 30038789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis.
    Oey O; Rao P; Luciuk M; Mannix C; Rogers NM; Sagar P; Wong A; Rangan G
    Exp Biol Med (Maywood); 2018 Mar; 243(5):428-436. PubMed ID: 29436846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
    Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
    Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
    Wicks P; Rasouliyan L; Katic B; Nafees B; Flood E; Sasané R
    BMC Res Notes; 2016 Sep; 9(1):434. PubMed ID: 27604188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study.
    Makhani N; Schreiner T
    Pediatr Neurol; 2016 Apr; 57():101-4. PubMed ID: 26996405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial.
    Højsgaard Chow H; Talbot J; Lundell H; Gøbel Madsen C; Marstrand L; Lange T; Mahler MR; Buhelt S; Holm Hansen R; Blinkenberg M; Romme Christensen J; Soelberg Sørensen P; Rode von Essen M; Siebner HR; Sellebjerg F
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.